Sign In
Buy ATAI
$4.53
-0.280 (-5.82%)
At Close: Jun 03, 2026
Behind the Wall: Psychedelics Have “Absolutely Transformational” Potential
10:42am, Thursday, 11'th Nov 2021
Is now the time to invest in psychedelic stocks? Dustin Robinson, founder of venture capital firm Iter Investments, says yes and explains why.
NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders
atai Life Sciences to Participate in Upcoming November Investor Conferences
04:30pm, Friday, 05'th Nov 2021
NEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders
This Psychedelics Stock Was Up More Than 20% Last Week, Outperforming Tesla, Nvidia and GameStop
04:43pm, Tuesday, 02'nd Nov 2021
Psychedelics have picked up more and more momentum on Wall Street, with famed investors such as Kevin O'Leary and Peter Thiel recognizing the potential in the psych drug industry. Psychedelic drugs,
What Is Precision Psychiatry? Biotech Company Leverages New Approach To Mental Health Disorders
03:45pm, Monday, 11'th Oct 2021
Atai Life Sciences (NASDAQ:ATAI), a biotech company in the psychedelics space, announced the formation of a new subsidiary, called PsyProtix. PsyProtix is a precision psychiatry company focused on dev
Atai Life Launches Depression-Focused Firm
10:42am, Monday, 11'th Oct 2021
Atai Life Sciences NV (NASDAQ: ATAI) has launched PsyProtix, a new platform company formed with Chymia LLC, a Duke University biotechnology spinout. PsyProtix is a precision psychiatry company f
NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, to
Can Ketamine For Depression Be Improved? New Study Will Looks Into Ketamine Analog Arketamine
02:59pm, Tuesday, 14'th Sep 2021
Perception Neuroscience, an Atai Life Sciences (NASDAQ:ATAI) subsidiary, is starting a Phase 2a clinical trial on PCN-101, its lead drug candidate. The study will evaluate the safety and efficacy of a
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression
08:00am, Tuesday, 14'th Sep 2021
NEW YORK and BERLIN, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Perception Neuroscience (Perception), an atai Life Sciences (atai) biopharmaceutical company focused on developing innovative therapies in neuro
BERLIN and SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health d
Time to Buy the Magic Stocks? Magic Mushrooms, That Is.
12:39pm, Wednesday, 08'th Sep 2021
The first state to legalize cannabis for medical use was California, in 1996. In 2001, medical marijuana was approved in Canada.
atai Life Sciences to Participate in Upcoming September Investor Conferences
06:00pm, Friday, 03'rd Sep 2021
BERLIN, Sept. 03, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,
Atai shares pop after earnings: Company's CEO talks about mental health and psychedelics
04:22pm, Monday, 16'th Aug 2021
Atai Life Sciences, a biopharmaceutical and psychedelic company reported its first earnings since going public in June. Florian Brand, Atai's CEO and co-founder joins Closing Bell to discuss the futur
Atai Life Sciences N.V. (ATAI) CEO Florian Brand on Q2 2021 Results - Earnings Call Transcript
03:27pm, Monday, 16'th Aug 2021
Atai Life Sciences N.V. (ATAI) CEO Florian Brand on Q2 2021 Results - Earnings Call Transcript
3 Disruptive Mental Health Stocks to Consider Buying Before They're Huge
09:34am, Saturday, 14'th Aug 2021
They're the first pioneers in exciting new markets.
